Axa S.A. Biocryst Pharmaceuticals Inc Transaction History
Axa S.A.
- $32.8 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
254Shares Held
181MCall Options Held
839KPut Options Held
816K-
Black Rock Inc. New York, NY18.4MShares$132 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.7MShares$126 Million0.0% of portfolio
-
State Street Corp Boston, MA17.5MShares$125 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY13.1MShares$93.2 Million0.8% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$72.3 Million0.65% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.33B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...